Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year net income growth rate
Percentile
P85
Within normal range
vs 2Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 45.49% |
| Q3 2025 | -56.97% |
| Q2 2025 | 58.94% |
| Q1 2025 | -145.98% |
| Q4 2024 | 61.22% |
| Q3 2024 | 9.31% |
| Q2 2024 | 16.53% |
| Q1 2024 | -50.83% |
| Q4 2023 | 46.45% |
| Q3 2023 | -33.59% |
| Q2 2023 | -9.48% |
| Q1 2023 | 46.53% |
| Q4 2022 | -22.77% |
| Q3 2022 | -107.77% |
| Q2 2022 | 35.20% |
| Q1 2022 | -18.33% |
| Q4 2021 | -32.00% |
| Q3 2021 | 40.21% |
| Q2 2021 | -114.00% |
| Q1 2021 | 54.81% |
| Q4 2020 | -14.15% |
| Q3 2020 | -28.24% |
| Q2 2020 | -49.93% |
| Q1 2020 | 21.21% |
| Q4 2019 | -220.00% |
| Q3 2019 | 57.37% |
| Q2 2019 | -9.82% |
| Q1 2019 | -67.73% |
| Q4 2018 | 5.86% |
| Q3 2018 | -49.13% |
| Q2 2018 | 44.95% |
| Q1 2018 | -21.07% |
| Q4 2017 | -0.88% |
| Q3 2017 | -10.33% |
| Q2 2017 | -22.14% |
| Q1 2017 | -52.84% |
| Q4 2016 | 9.89% |
| Q3 2016 | -37.40% |
| Q2 2016 | 35.25% |
| Q1 2016 | -71.05% |